Is Beta Bionics, Inc. (BBNX) a Buy, Sell, or Hold?
NASDAQ : BBNX
Beta Bionics, Inc.
$15.9 USD
$1.79 (12.69%)
- Volume
- 1.27M
- Average Volume
- 942.09K
- Market Capitalization
- $715.34M
- P/E Ratio
- -9.46
- Dividend Yield
- 0.00%
- Price Target
- $21.00
- Year High
- $32.71
- Year Low
- $8.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.88
Company Overview
NASDAQ
Sean T. Saint
Medical - Devices
Healthcare
BBNX
423
US
USD
Liquidity Metrics
0.03
8.88
7.96
1.70
0.00
Sales & Valuation
$100.25M
6.01
2.76
-11.65
-1.38
Profitability
-$1.81
-$73.2M
-61.32%
-61.32%
-26.30%
-24.96%
P/E Metrics
-9.46
7.70
7.70
Analyst Price Target & Rating
$21.00
$22.00
$14.00
2/5
8 Analysts
-24.29%
Financial Health Scores
10.33
2/9
$205.02M
$292.39M
$36.02M
-$75.15M
Key Metrics (TTM)
$677.53M
5.69
-9.44
8.88
-26.30%
-30.98%
-10.30%
-8.58%
198 days
Company Executives
| Name | Title |
|---|---|
| Sean T. Saint | President, Chief Executive Officer & Director |
| Mike Mensinger | Chief Product Officer |
| David Henderson | Vice President of Operations |
| Mark Hopman | Chief Commercial Officer |
| Stephen H. Feider | Chief Financial Officer, Treasurer & Secretary |
| Blake Beber | Head of Investor Relations |
| Steven Russell | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Beta Bionics, Inc. (NASDAQ:BBNX) Stock
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To suppor ... t its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Beta Bionics, Inc. (NASDAQ:BBNX) Receives Average Rating of “Moderate Buy” from Analysts
2026-08-03 04:16:14
Beta Bionics, Inc. (NASDAQ: BBNX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
2026-07-30 08:48:00
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.
Beta Bionics, Inc. (BBNX) Q2 2026 Earnings Call Transcript
2026-07-30 01:33:14
Beta Bionics, Inc. (BBNX) Q2 2026 Earnings Call Transcript
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates
2026-07-29 18:11:08
Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to a loss of $0.39 per share a year ago.
Beta Bionics Q2 Earnings Call Highlights
2026-07-29 18:05:05
Beta Bionics NASDAQ: BBNX reported second-quarter 2026 net sales of $32 million, up approximately 38% from a year earlier, as new patient starts and recurring pharmacy-channel supply revenue supported growth for its iLet insulin-delivery system.
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
2026-07-29 16:02:00
IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2026 and updated its full year guidance for the year ending December 31, 2026.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
2026-07-01 11:28:00
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
2026-07-01 08:30:00
IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026.
Frequently Asked Questions
-
What is the current Beta Bionics, Inc. (BBNX) stock price?
-
Beta Bionics, Inc.(NASDAQ:BBNX) stock price is $15.9 in the last trading session. During the trading session, BBNX stock reached the peak price of $32.71 while $8.8 was the lowest point it dropped to. The percentage change in BBNX stock occurred in the recent session was 12.69% while the dollar amount for the price change in BBNX stock was $1.79.
-
BBNX's industry and sector of operation?
-
The NASDAQ listed BBNX is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of BBNX?
-
Sean T. Saint | President, Chief Executive Officer & Director
Mike Mensinger | Chief Product Officer
David Henderson | Vice President of Operations
Mark Hopman | Chief Commercial Officer
Stephen H. Feider | Chief Financial Officer, Treasurer & Secretary -
How many employees does BBNX have?
-
Number of BBNX employees currently stands at 423. BBNX operates from 11 Hughes, Irvine, CA 92618, US.
-
Link for BBNX official website?
-
Official Website of BBNX is: https://www.betabionics.com
-
How do I contact BBNX?
-
BBNX could be contacted at phone #949 427 7785 and can also be accessed through its website. BBNX operates from 11 Hughes, Irvine, CA 92618, US.
-
How many shares of BBNX are traded daily?
-
The average number of BBNX shares traded daily for last 3 months was 942.09K.
-
What is the market cap of BBNX currently?
-
The market value of BBNX currently stands at $715.34M with its latest stock price at $15.9